Press Release

Nicox Announces Shareholder Q&A Webpage
Available
August 26, 2025 – release at 7:30 am CET
Sophia Antipolis, France


Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology
company, today announced that a new webpage “Q&A” is available on the company’s website,
www.nicox.com, including information on the most frequently asked questions for shareholders
in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Q&A

Any investor questions can be addressed to communications@nicox.com.


About Nicox


Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost
eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension
Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical
research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product,
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other
territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to
Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese, and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the
CAC Healthcare index.

For more information www.nicox.com


Analyst coverage


H.C. Wainwright & Co Yi Chen New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally,
the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the
information contained in analyst reports.

Contacts


Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com



Disclaimer




www.nicox.com
The information contained in this document may be modified without prior notice. This information includes forward-looking
statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current
expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors,
officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any
forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024”
which is available on Nicox’s website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the
French language version shall prevail.


Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00




www.nicox.com